|
FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
Cardiac Innovations Australia will promote sales of CardioComm Solutions’ Software into local Hospitals and Physician Based Institutions
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram (“ECG”) acquisition and management software solutions, today announced that is has signed an agency agreement with Cardiac Innovations Australia Pty. Ltd. (“Cardiac Innovations”), a distributor of medical hardware and software solutions into local hospitals and clinics in Australia.
CardioComm Solutions acknowledged the Cardiac Innovations relationship once it was confirmed this distributor had successfully obtained an Australian Register of Therapeutic Goods Certificate from the Department of Health, Therapeutics Goods Administration (“TGA”). TGA clearance is the required regulatory approval for the sale of any of CardioComm Solutions’ products into the Australian medical market. The agreement with Cardiac Innovations also makes provision for the future sale of other CardioComm Solutions products and solutions with additional TGA clearances.
Cardiac Innovations sells into a diverse Australian customer base that includes cardiologists, hospitals, electrophysiologists and primary care physicians. Their initial focus with GEMS™ WIN will be on marketing into organizations active in cardiac device implantation and follow-up as well as supporting surveillance in the unexplained syncope and post-ablation patient population.
Cardiac Innovations’ interest to become an agent for distribution of the CardioComm Solutions products was in response to a number of Australian medical groups looking for access to the GEMS™ WIN technologies as an alternative, proven and well priced solution that would address their unmet performance and customer support needs. “While the market in Australia is quite diverse, it is currently dominated by one arrhythmia monitoring solution,” notes the Managing Director for Cardiac Innovations Australia. “Without local access to a complete cardiac monitoring solution which supports reporting, inventory tracking and varied patient ECG monitoring options, many Australian customers have looked outside the country by attending international conferences or have undertaken training in the United States and Canada through which they were exposed to the CardioComm Solutions’ portfolio of products. Other companies in Australia are unable to offer a complete and competitive product for the cardiac rhythm market and this is where the GEMS™ WIN arrhythmia monitoring solution will give us a significant and differentiated competitive advantage.”
CardioComm Solutions has reported that a global distribution channel is an important element of their ongoing sales expansion strategy. Securing a local agent to provide GEMS™ WIN sales, technical assistance and customer support in Australia is a competitive advantage for CardioComm Solutions and well positions Cardiac Innovations to realize strong market gains with future expansion potential across the Asia Pacific region.
download pdf 
CardioComm Solutions' patented and proprietary
technology is used in products for recording,
viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products
are sold worldwide through a combination of an
external distribution network and a North
American-based sales team. The Company has
earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA
market clearance for its software devices.
CardioComm Solutions is headquartered in
Toronto, Canada, with offices in Victoria,
B.C.
FOR FURTHER
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com
Forward-looking
statements
This release may contain certain forward-looking
statements and forward looking information with
respect to the financial condition, results of
operations and business of CardioComm Solutions
and certain of the plans and objectives of
CardioComm Solutions with respect to these
items. Such statements and information reflect
management's current beliefs and are based on
information currently available to management.
By their nature, forward-looking statements and
forward-looking information involve risk and
uncertainty because they relate to events and
depend on circumstances that will occur in the
future and there are many factors that could
cause actual results and developments to differ
materially from those expressed or implied by
these forward-looking statements and
forward-looking information.
In evaluating these statements, readers should:
specifically consider risks discussed under the
heading "Risk Factors" in the Company's Annual
Information Form, available at www.sedar.com;
not to place undue reliance on forward-looking
statements and forward-looking information; be
aware. the Company does not assume any
obligation to update the forward-looking
statements and forward-looking information
contained in this Annual Information Form other
than as required by applicable laws (including
without limitation Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure
Obligations).
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of
this release.
|
